glp-1 news november 2025 today Receptor Agonists and vision risk GLP-1 Pipeline Update: August 2025

Cardiovascular outcomes The EXSCEL trial evaluated the cardiovascular safety of once-weekly exenatide (Bydureon)

An oral form of tirzepatide is still in clinical trials

pylori infection progression, fer-1, liproxstatin-1, DFO, and NAC can influence GC progression through various mechanisms and plays a crucial role in its development

The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial

The oncedaily Wegovy pill an oral formulation of semaglutide positions the company ahead of its closest rival, Eli Lilly, at a moment when demand for GLP1 therapies is accelerating worldwide

Thats what you want, right